Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Jeff P. Sharman, MD, Leonard M. Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Julie Di Paolo, PhD, Clarence Eng, MPH, Jing Hu, PhD, Jing He, Anita Reddy, PhD, Christopher A. Yasenchak, MD

Blood (2015) 126 (23): 4152.

https://doi.org/10.1182/blood.V126.23.4152.4152

Published: 2015

Journal Articles

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Jeff P. Sharman, MD, Andrei R. Shustov, MD, Mitchell R. Smith, MD PhD, Thomas E. Boyd, MD, Christopher Hagenstad, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Jing Hu, PhD, Anita Reddy, PhD, Siddhartha Mitra, MDPhD, Christopher A. Yasenchak, MD, Farrukh T. Awan, MD MS

Blood (2015) 126 (23): 1744.

https://doi.org/10.1182/blood.V126.23.1744.1744

Published: 2015

Journal Articles

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Jeff P. Sharman, MD, Leonard Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Michael J. Hawkins, MD, Julie A Di Paolo, PhD, Jing Hu, Ph.D, Anita Reddy, PhD, Feng Jin, PhD, Flordeliza Melchor-Khan, BS, Christopher A. Yasenchak, MD

Blood (2013) 122 (21): 1634.

https://doi.org/10.1182/blood.V122.21.1634.1634

Published: 2013

Journal Articles

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

Gabriela M. Baerlocher, MD, Elisabeth Oppliger Leibundgut, PharmD, Christina Ayran, Martha Blaney, PharmD, Bart Burington, Ph.D, Dianne Morfeld, Olatoyosi Odenike, MD, Oliver Ottman, MD, Anita Reddy, PhD, Alexander Roeth, MD, Gary Spitzer, MD, Monic J. Stuart, MD, MPH, Srdan Verstovsek, MD, PhD, David S. Snyder, MD

Blood (2012) 120 (21): 179.

https://doi.org/10.1182/blood.V120.21.179.179

Published: 2012

Journal Articles

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Carol Ann Huff, M.D., Quiju Wang, MS, Ashraf Z. Badros, MD, Richard J. Jones, Anita Reddy, PhD, Kevin Nishimoto, PhD, Monic J. Stuart, MD, MPH, Stephen M Kelsey, MD, William Matsui, MD

Blood (2012) 120 (21): 4898.

https://doi.org/10.1182/blood.V120.21.4898.4898

Published: 2012

Journal Articles

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

H. Jean Khoury, MD, FACP, Robert H. Collins, Jr, MD, William Blum, MD, Lori Maness, MD, Patrick Stiff, MD, Stephen M. Kelsey, MD, Anita Reddy, PhD, Jennifer A. Smith, PhD, John F. DiPersio, MD, PhD

Blood (2010) 116 (21): 2190.

https://doi.org/10.1182/blood.V116.21.2190.2190

Published: 2010

NARROW

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only